

## Special Issue

# New Immunological Therapeutic Strategies in Kidney Disease

### Message from the Guest Editor

A new FDA-approved immunotherapy stabilizes kidney function in patients with IgA nephritis by suppressing intestinal immune system overactivity. In addition, targeting the IL-23/IL-17 pathway has shown promise in treating immune-mediated kidney diseases. Blocking IL-23 signaling in renal tubular epithelial cells can create an immune regulatory microenvironment in the kidney, effectively treating renal autoimmune disease. Also, chimeric antigen receptor (CAR) T-cell therapy is being adapted for kidney diseases. This approach can target autoreactive immune cells or restore immune tolerance. Furthermore, mesenchymal stem cells are being investigated for their potential to modulate chronic kidney disease progression through immunomodulatory, anti-fibrotic, anti-inflammatory, antioxidant, anti-apoptotic, and angiogenic properties. These emerging strategies represent a shift towards more targeted and personalized approaches for treating immune-mediated kidney diseases, potentially offering improved outcomes for patients with various renal conditions.

### Guest Editor

Dr. Yasunari Matsuzaka

Department of Microbiology and Immunology, Showa Medical University Graduate School of Medicine, Shinagawa-ku, Tokyo 142-8555, Japan

### Deadline for manuscript submissions

31 December 2025



## Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/225750](https://mdpi.com/si/225750)

*Current Issues in Molecular  
Biology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cimb@mdpi.com](mailto:cimb@mdpi.com)

[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)





# Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,  
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,  
New Zealand

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC,  
PubMed, Embase, CAPus / SciFinder, FSTA, AGRIS, and  
other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 17.8 days after  
submission; acceptance to publication is undertaken in 2.7  
days (median values for papers published in this journal in  
the first half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and  
reviewer names are published annually in the journal.